Newborn screening algorithm distinguishing potential symptomatic isovaleric acidemia from asymptomatic newborns.
analysis of variance
isovaleric acidemia
isovaleryl‐CoA dehydrogenase
newborn screening
Journal
Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918
Informations de publication
Date de publication:
24 Sep 2024
24 Sep 2024
Historique:
revised:
25
08
2024
received:
12
04
2024
accepted:
05
09
2024
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
25
9
2024
Statut:
aheadofprint
Résumé
Newborn screening (NBS) for isovaleric acidemia (IVA) reduces mortality and morbidity; however, it has also resulted in the detection of individuals with an asymptomatic or mild presentation for which early detection via newborn screening has not been proven to alter neurological outcome. We reevaluated biochemical and molecular data for newborns flagged positive for IVA in aim of developing a new screening algorithm to exclude the latter from positive screening. Among 2 794 365 newborns underwent routine newborn screening in Israel, 412 flagged positive for IVA, of which, 371 were false positives on recall sample testing and 41 positive newborns were referred to the clinic. 38/41 have biochemical and molecular confirmation in keeping with IVA. Among the 38 patients, 32% (12/38) were classified as symptomatic while, 68% (26/38) were classified as asymptomatic. 69% of the latter group harbor the known variant associated with mild potentially asymptomatic phenotype, c.932C>T; p. Ala311Val. Among asymptomatic patients, only 46% (12/26) are currently treated. Two novel variants have been detected in the IVD gene: c.487G>A; p. Ala163Thr and c.985A>G; p. Met329Val. Cut-off recalculation, of referred newborns' initial biochemical results, after classifying the referred patients to two binary groups of symptomatic and asymptomatic, resulted in an improved NBS algorithm comprising of C5 >5 μM and C5/C2>0.2 and C5/C3>4 flagging only those likely to have the classic symptomatic phenotype.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 SSIEM.
Références
Schlune A, Riederer A, Mayatepek E, Ensenauer R. Aspects of newborn screening in Isovaleric Acidemia. Int J Neonatal Screen. 2018;4(1):7. doi:10.3390/ijns4010007
Kraus JP, Matsubara Y, Barton D, et al. Isolation of cDNA clones coding for rat isovaleryl‐CoA dehydrogenase and assignment of the gene to human chromosome 15. Genomics. 1987;1(3):264‐269. doi:10.1016/0888‐7543(87)90053‐x
Vockley J, Rogan PK, Anderson BD, et al. Exon skipping in IVD RNA processing in isovaleric acidemia caused by point mutations in the coding region of the IVD gene. Am J Hum Genet. 2000;66(2):356‐367. doi:10.1086/302751
Moorthie S, Cameron L, Sagoo GS, Bonham JR, Burton H. Systematic review and meta‐analysis to estimate the birth prevalence of five inherited metabolic diseases. J Inherit Metab Dis. 2014;37(6):889‐898. doi:10.1007/s10545‐014‐9729‐0
Mütze U, Henze L, Gleich F, et al. Newborn screening and disease variants predict neurological outcome in isovaleric aciduria. J Inherit Metab Dis. 2021;44(4):857‐870. doi:10.1002/jimd.12364
Mütze U, Garbade SF, Gramer G, et al. Long‐term outcomes of individuals with metabolic diseases identified through newborn screening. Pediatrics. 2020;146(5):e20200444. doi:10.1542/peds.2020‐0444
Ensenauer R, Vockley J, Willard JM, et al. A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. Am J Hum Genet. 2004;75(6):1136‐1142. doi:10.1086/426318
Mohsen AW, Anderson BD, Volchenboum SL, et al. Characterization of molecular defects in isovaleryl‐CoA dehydrogenase in patients with isovaleric acidemia. Biochemistry. 1998;37(28):10325‐10335. doi:10.1021/bi973096r
Mütze U, Henze L, Schröter J, et al. Isovaleric aciduria identified by newborn screening: strategies to predict disease severity and stratify treatment. J Inherit Metab Dis. 2023;46(6):1063‐1077. doi:10.1002/jimd.12653
Couce ML, Aldamiz‐Echevarría L, Bueno MA, et al. Genotype and phenotype characterization in a Spanish cohort with isovaleric acidemia. J Hum Genet. 2017;62(3):355‐360. doi:10.1038/jhg.2016.144
Staretz‐Chacham O, Daas S, Ulanovsky I, et al. The role of orotic acid measurement in routine newborn screening for urea cycle disorders. J Inherit Metab Dis. 2021;44(3):606‐617. doi:10.1002/jimd.12331
Richards S, Aziz N, Bale S, et al. ACMG laboratory quality assurance committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405‐424. doi:10.1038/gim.2015.30
Cohen BE, Szeinberg A, Berman W, et al. Mental retardation in a family with phenylketonuria and mild hyperphenylalaninemia. Pediatrics. 1969;44(5):655‐660.
Bonham JR, Carling RS, Lindner M, et al. Raising awareness of false positive newborn screening results arising from pivalate‐containing creams and antibiotics in Europe when screening for isovaleric acidaemia. Int J Neonatal Screen. 2018;4(1):8. doi:10.3390/ijns4010008
Chen T, Fan C, Huang Y, et al. Genomic sequencing as a first‐tier screening test and outcomes of newborn screening. JAMA Netw Open. 2023;6(9):e2331162. doi:10.1001/jamanetworkopen.2023.31162